FEDR-MF-002/FREEDOM-2

About this trial

Patient Profile

Primary Myelofibrosis Post-Polycythemia Vera Myelofibrosis

Where’s this trial being run?

Cork University Hospital, St James’s Hospital, and Mater Misericordiae University Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.


Summary Data

Name: FEDR-MF-002/FREEDOM-2
Number: CTRIAL-IE 19-40
Full Title:

A phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy in subjects with DIPSS-intermediate or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis and previously treated with ruxolitinib

Principal Investigator: Eibhlin Conneally
Type: Industry Sponsored
Sponsor:

Celgene

Recruitment Started: Global:
Ireland:
Global Recruitment Target: 192
Ireland Recruitment Target: 6